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Pharmacokinetics of human leptin in mice and
rhesus monkeys
B Ahre´n1, RM Baldwin2 and PJ Havel3
1Department of Medicine, Lund University, Malmo¨, Sweden; 2Department of Molecular Biosciences, School of Veterinary Medicine,
University of California, Davis, CA, USA; and 3Department of Nutrition, University of California, Davis, CA, USA
OBJECTIVE: The pharmacokinetic characteristics of human leptin were examined in rhesus monkeys and in C57BL=6J
mice fed a normal chow or a high-fat diet.
DESIGN: For the monkey study, in nine rhesus monkeys (body weight 12.4 2.4 kg; mean s.d.), recombinant met-
human leptin was injected intravenously or subcutaneously (1 mg=kg). For the mouse study, after 6 months of feeding
C57BL=6J mice a high-fat diet (body weight 32.9 3.6 g; n 8) or a control diet (24.5 1.2 g; n 6), recombinant met-
human leptin was administered intraperitoneally (10 mg=g). Blood samples were collected for leptin measurement at
specific time points after leptin administration.
MEASUREMENTS: Plasma leptin concentrations were determined by radioimmunoassay and pharmacokinetic
analysis was performed.
RESULTS: Disposition of human leptin in rhesus monkeys was biphasic following intravenous administration, with a
terminal phase half-life of 96.4 16.5 min and clearance of 1.8 0.2 ml=min=kg. Subcutaneously administered leptin
was absorbed slowly, perhaps by a zero-order process as leptin levels appeared to plateau and remained elevated
throughout the 8 h sampling period. In C57BL=6J mice, the absorption and elimination of human leptin were both first-
order following intraperitoneal administration. Pharmacokinetic parameters did not differ between normal-weight
mice fed a chow diet and obese mice fed a high-fat diet. The elimination half-life was 47.0 26.4 min in mice fed a high-
fat diet and 49.5 12.0 min in mice fed a control diet.
CONCLUSION: The kinetics of leptin in rhesus monkeys were biphasic and clearance was similar to values previously
reported in humans. The estimated half-life was 96.4 min in rhesus monkeys and 49.5 min in normal weight mice. The
was no difference in leptin kinetics between high-fat fed and control mice, suggesting that the increased baseline
leptin levels in the obese mice are due to increased leptin production and secretion.
International Journal of Obesity (2000) 24, 1579–1585
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Introduction
Leptin is encoded by the ob gene and expressed
mainly in adipose tissue.1,2 It is released from the
adipocytes in proportion to recent energy intake2 – 5
and acts primarily in the central nervous system to
reduce food intake and stimulate energy expenditure,
thereby participating in the regulation of energy
balance and body weight.6 – 8 In obesity, the circulat-
ing levels of leptin are increased, which has been
thought to be due to increased synthesis and release
from the adipocytes as well as increased adipose mass
per se.2,9 – 11 Leptin production is regulated by insu-
lin,12,13 an effect that appears to involve insulin’s
action to increase glucose metabolism in adipose
tissue.14 In humans, circulating leptin concentrations
are correlated with circulating insulin15,16 and 24 h
circulating leptin levels are increased after high-
carbohydrate meals, which induce larger postprandial
insulin and glycemia excursions than high-fat meals.17
However, the extent to which changes of circulating
leptin kinetics contribute to variations of leptin
observed with changes of adiposity, energy intake,
insulin or dietary macronutrient composition is
not clear, in part because the pharmacokinetics of
circulating leptin are not well characterized.
Previous studies using radiolabeled leptin have
reported significantly different leptin plasma half-
lives, both across and within species. A study in
humans reported a half-life of circulating leptin of
25 min.18 Two studies in mice suggested the consider-
ably longer half-lives of 1.5 and 3 h,19,20 whereas a
recently published study in Zucker rats reported a
much shorter half-life of circulating leptin ( 6 min)
with no difference between lean and obese animals.21
Much of the disparity in the literature is attributable to
a wide range of methodologies and study objectives,
with half-life being determined secondarily, often
based on a minimal number of time points. In this
study, we have examined the pharmacokinetic char-
acteristics of human leptin after intravenous or sub-
cutaneous administration to rhesus monkeys. To our
knowledge, the pharmacokinetics of leptin have not
been previously characterized in nonhuman primates.
As it has been suggested that alterations in leptin
kinetics may account for the elevated plasma leptin
*Correspondence: B Ahre´n, Department of Medicine, Malmo¨
University Hospital, S-205 02 Malmo¨, Sweden.
E-mail: Bo.Ahren@medforsk.mas.lu.se
Received 16 December 1999; revised 19 May 2000;
accepted 7 July 2000
International Journal of Obesity (2000) 24, 1579–1585
ß 2000 Macmillan Publishers Ltd All rights reserved 0307–0565/00 $15.00
www.nature.com/ijo
levels observed with obesity, we have also compared
the pharmacokinetic characteristics of recombinant
human leptin after a single intraperitoneal injection
in C57BL=6J mice fed either a normal chow diet or a
high-fat diet. Mice with increased adiposity resulting
from high-fat feeding were examined because it is
known that circulating levels of leptin are markedly
elevated by the high-fat feeding in conjunction with
the development of moderate obesity and severe
glucose intolerance.22 – 25 Thus, this model allowed
us to observe potential changes in leptin pharmaco-
kinetics occurring in these animals with markedly
elevated steady-state levels of endogenous leptin.
Pharmacokinetic parameters were established by com-
partmental and noncompartmental analysis of the
circulating leptin levels after a single intraperitoneal,
intravenous or subcutaneous injection.
Methods
Monkey study
Nine healthy adult (age 7 – 17 y) male rhesus monkeys
(Macaca mulatta) weighing between 8.9 and 16.0 kg
(12.4 2.4 kg; mean s.d.) were used for these stu-
dies. Prior to selection for the study, a physical
examination, complete blood count and serum bio-
chemistry panel were performed on each animal. The
animals had previously been acclimated to several
hours of chair restraint with a minimum of 10 training
sessions.26 Animals were housed in the AAALAC
accredited facilities of the California Regional Pri-
mate Research Center (CRPRC) in accordance with
standards established by the US Animal Welfare Act
and the Institute of Laboratory Animal Resources
(ILAR). The experimental protocols were approved
by the institutional animal care and use committee at
the University of California Davis and the CRPRC.
Studies were conducted in accordance with the guide-
lines of the National Research Council’s Guide for the
Care and Use of Laboratory Animals. The experi-
ments with intravenous leptin were conducted first
and the experiments with subcutaneous leptin admin-
istration were conducted in the same animals at least 1
week later. For both studies, the animals were fasted
overnight and placed in restraint chairs 1 h before the
experiment. A cephalic vein was catheterized for
intravenous injection of leptin and for collection of
blood samples. Two baseline blood samples were
drawn from the venous catheter. Recombinant met-
human leptin (Amgen Inc., Thousand Oaks, CA) was
then administered rapidly intravenously or given as a
subcutaneous injection in the interscapular region
(both at 1 mg=kg body weight dissolved in saline).
Thereafter, blood samples were taken at 2, 5, 15, 30,
60, 90, 120, 180, 240, 300 and 360 min after dosing
while the animals were in the restraint chairs. The
animals were returned to their home cages after
360 min. The 480 min sample was collected by veni-
puncture while the animals remained caged. One of
the nine monkeys administered leptin intravenously
failed to demonstrate a log – linear elimination phase
in the 480 min sampling period, precluding our ability
to accurately determine rate constants from this
animal. Therefore, when calculating the pharmaco-
kinetic characteristics, only eight animals were used
in the intravenous administration series.
Mouse study
Female C57BL=6J mice were obtained from Bom-
holtgaard Breeding and Research Centre, Ry, Den-
mark, at 4 weeks of age. One week after arrival to the
Experimental Department at Lund University, Malmo¨,
mice were given either a high-fat diet (n 8) or an
ordinary rodent chow diet (n 6; Research Diets, N
Brunswick, NJ, USA). On a caloric base, the high-fat
diet consisted of 16.4% protein, 25.6% carbohydrates
and 58.0% fat (total 23.4 kJ=g), whereas the control
diet consisted of 25.8% protein, 62.8% carbohydrates
and 11.4% fat (total 12.6 kJ=g). Throughout the study
period, the mice had free access to food and water.
After 6 months, body weight was 24.5 1.2 g in mice
fed a normal chow and 32.9 3.6 g in mice fed a high-
fat diet. At this time, recombinant human leptin
(Amgen Inc., Thousand Oaks, CA) was injected
intraperitoneally at a dose level of 10 mg=g body
weight in a volume of 10ml=g body weight. Blood
samples were taken from the retro-orbital venous
plexus at 15, 60, 120, 180, 360 and 480 min after.
Plasma was immediately separated following a cen-
trifugation at 4C and stored at ÿ20C until analysis.
The study was approved by the Animal Ethics
Committee at Lund University.
Leptin analysis
In the monkey study, plasma levels of human leptin
were determined with a radioimmunoassay for pri-
mate leptin (Linco Research Inc., St Charles, MO,
USA). The method uses a polyclonal rabbit antibody
raised against recombinant human leptin,125I-labeled
tracer prepared with recombinant human leptin and
human leptin as standard. Compared with the standard
Linco human leptin assay,27 the primate leptin assay
has been demonstrated to display 100% cross-reactiv-
ity with recombinant and endogenous human leptin.
Rabbit anti-rabbit IgG was used for separation of
bound and free leptin (Linco). In the mouse study,
pre-treatment plasma leptin levels were determined
with a radioimmunoassay specific for murine leptin
(Ahre´n et al,23 Linco Research Inc., St Charles, MO).
The method uses a polyclonal rabbit antibody raised
against recombinant murine leptin,125I-labeled tracer
prepared with recombinant mouse leptin and mouse
leptin as standard. Rabbit anti-rabbit IgG was used for
separation of bound and free leptin. The Linco human
leptin assay27 was used to measure leptin in mouse
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plasma samples collected after the administration of
recombinant human leptin.
Calculations and statistics
Pharmacokinetic analysis of the leptin concentration
vs time data was performed using a nonlinear least-
squares regression program (WinNonlin, Scientific
Consulting Inc., Apex, NC) with weighting of the
data proportional to 1=Cp, where Cp is the plasma
leptin level. Pharmacokinetic parameters were derived
using the methods described by Gibaldi.28 The equa-
tions CpC0e-k10t and CpAe-atBe-bt were used to
describe a one-compartment and two-compartment
open model, respectively. Volumes of distribution
were calculated as follows: Vd dose=(AB),
VAUC dose=(bAUCinf), and for intraperitoneally
administered leptin V=f dose=(k10AUCinf). Since
the extent of intraperitoneal absorption could not be
determined without repeating the mouse experiment
with intravenous leptin administration, clearance (Cl)
and volume of distribution (V) are reported as Cl=f
and V=f, with f representing the fraction absorbed. For
noncompartmental analysis the terminal log – linear
phase was extrapolated to infinity to determine the
area under the first moment curve (AUMCinf). Data
are reported as mean s.d. Differences between high-
fat fed and normal-diet controls were evaluated using
the two-sample Student t-test.
Results
Monkey study
Disposition of recombinant human leptin in monkeys
following intravenous administration (Figure 1,
upper panel) is characterized by a two compart-
ment open model with a distribution phase
(t1=2(a) 10.4 1.8 min) and a slower elimination
phase (t1=2(b) 96.4 16.5 min). The calculated
pharmacokinetic constants are reported in Table 1.
The kinetics of circulating leptin following subcuta-
neous injection are shown in the lower panel of Figure
1. Given the slow rate of absorption, the sampling
period was not of sufficient length to obtain points
during the log – linear elimination phase and hence the
Cmax (peak concentration) and Tmax (time to peak
concentration) were the only calculated parameters.
Plasma leptin increased from a pre-injection con-
centration of 7.6 5.3 ng=ml to a peak value of
544 43 ng=ml. From visual inspection of the dataset,
Cmax values ranged from 378 to 712 ng=ml with Tmax
values occurring from 90 to 480 min post-injection.
Table 1 Pharmacokinetic characteristics of recombinant met-human leptin administered
intravenously (1 mg=kg body weight) to monkeys (n8)
Parameter Units Mean s.d.
Body weight kg 12.02.4
a minÿ1 0.0680.011
t1=2(a) min 10.41.8
b minÿ1 0.0070.001
t1=2(b) min 96.416.5
AUCINF mgmin=ml 55461.5
AUMCINF mgmin2=ml 42.68.8
Clearance ml=min=kg 1.820.20
Vd ml=kg 50.69.2
VAUC ml=kg 253.852.8
Vss ml=kg 139.825.2
MRTINF min 76.711.3
AUC area under the curve; AUMCarea under the first moment curve; MRTmean
residence time. Means s.d. are shown.
Figure 1 Plasma concentrations of human leptin before and
after the intravenous (upper panel; n 8) or subcutaneous (lower
panel; n9) injection of recombinant human leptin (1 mg=kg) in
male rhesus monkeys. Means s.e.m. are shown.
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Mouse study
Following intraperitoneal injection, plasma leptin con-
centrations in mice were best described by a one
compartment open model with first order absorption
and elimination (Figure 2). Mean pharmacokinetic
values for mice fed either a control or a high fat
diet are reported in Table 2. The absorption rate
constant k01 and t1=2 (k01) are not reported because
the sampling of mouse blood was focused on accu-
rately determining leptin elimination kinetics, and
hence the absorption phase was only partially defined.
With the exception of the higher baseline levels of
mouse leptin in mice fed a high-fat diet, the para-
meters were not significantly altered by diet. Plasma
clearance and the elimination half-life in high-fat
fed mice were 10.7 1.4 ml=min=kg and 47.0
26.4 min, respectively. Values for normal diet controls
were 10.6 1.4 ml=min=kg and 49.5 12.0 min,
respectively.
Discussion
In this study, we observed biphasic kinetics following
intravenous administration of recombinant human
leptin to rhesus monkeys. The half-lives for the
distribution phase t1=2 (a) and the terminal elimination
phase t1=2(b) were 10.4 1.8 min and 96.4 16.5 min,
respectively, and the mean residence time was
76.7 11.3 min. To our knowledge these results pro-
vide the first report of the pharmacokinetics of leptin
in nonhuman primates. Comparison of our pharmaco-
kinetic data with other studies using rodents or
humans is difficult in some cases since a number of
different methods to describe leptin kinetics have been
employed. For example, a study in humans using an
arteriovenous balance approach to determine endo-
genous leptin production on a per kg body fat basis,
reported a leptin plasma half-life of 25 min and
clearance of 1.5 ml=min=kg.11 As the authors state,
these values were considered estimates, as total body
fat in the subjects was determined allometrically and
the volume of distribution of leptin was assumed to be
the calculated plasma volume.
The most readily comparable studies modeling the
kinetics of exogenous leptin have been performed in
rats where it was administered intravenously (Table
3). Using Sprague – Dawley rats, Cumin et al29 admi-
nistered three different doses of leptin and sampled
blood for 3 h. Although their data best fit a three-
compartment model, for all three doses the pharma-
cokinetic constants, Vd, MRT, and the terminal phase
elimination half-life were all close to both one another
and to our study. In another study conducted in rats,
using a combination of arteriovenous balance and
intravenous administration, Zeng et al found that
leptin displayed biphasic kinetics.30 When these data
were reanalyzed and modeled using the same
approach employed in the current study, the calcu-
lated half-lives and mean residence times, although
slightly less, were comparable to our results (Landt
unpublished results). Similar values were obtained by
Hill et al using a dose that was approximately 1=1000
of those used in the current study and in the study
by Cumin et al.31 The shorter calculated half-lives
observed in these studies may simply be attributable
Table 2 Pharmacokinetic characteristics of recombinant met-human leptin when administered intraperitoneally (10 mg=g body
weight) to C57BL=6J mice fed a normal diet (n6) or a high-fat diet (n 8)
Parameter Units Normal diet High-fat fed P
Body weight g 24.51.2 32.9 3.6 <0.001
k10 min
ÿ1 0.0150.003 0.018 0.006 0.2832
t1=2(k10) min 49.512.0 47.0 26.4 0.8378
V=f ml=kg 756221 702 345 0.7424
Clearance ml=min=kg 10.61.4 10.7 1.4 0.8986
AUCinf ngmin=ml 961246123393 953157122953 0.9063
AUMCinf ngmin2=ml 11880926716203052 102161322 30313745 0.2483
MRTinf min 123.67.5 106.2 23.0 0.1018
Baseline Leptin ng=ml 10.43.3 42.9 23.6 0.0062
AUC area under the curve; AUMCarea under the first moment curve; MRTmean residence time.
Means s.d. are shown. P indicates the probability level of random difference between the groups.
Figure 2 Plasma concentrations of human leptin after the
intraperitoneal injection of recombinant human leptin (10mg=g)
in C57BL=6J mice fed a normal chow diet (n6) or a high-fat diet
(n8) for 6 months. Means s.e.m. are shown.
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to a shorter sampling period, and hence the terminal
elimination phase was defined by a minimal number
of later time points.
It is clear from comparing several different studies,
using doses ranging over at least three orders of
magnitude, that the rates of elimination and mean
residence times are similar across species. The most
striking difference observed in the kinetics of leptin
in monkeys was a 68 – 74% lower plasma clearance
compared to the fairly consistent values obtained in
rats. It is noteworthy that clearance of 1.8 ml=min=kg
obtained in the monkeys is similar to the value of
1.5 ml=min=kg reported in the human arteriovenous
balance study.11 Several groups have shown approxi-
mately 80% of whole body leptin clearance in humans
and rats can be attributed to renal elimination.30 – 33
However, the relative contributions of glomerular
filtration and secretion to renal leptin clearance have
been the subject of debate. Meyer et al reported an
inverse relationship between renal fraction leptin
extraction and circulating leptin level, and have sug-
gested that renal uptake is a saturable process mod-
elled by Michaelis – Menton kinetics.33 It is difficult to
reconcile these findings with our results which demon-
strate that plasma clearance is virtually the same in
monkeys as the value reported in humans, when
plasma leptin levels in the monkeys were 1 – 2
orders of magnitude higher.
Since clearance, rate of elimination and volume of
distribution are all directly related, VAUC and VSS, were
both reduced to a similar degree as clearance, despite
little differences in the initial volume of distribution
across species. Although significantly less compared to
rodents, the VSS of 140 ml=kg or 13.9% of body mass in
monkeys, indicates that leptin most likely distributes
beyond the plasma volume and throughout the extra-
cellular space. As the leptin assays employed are con-
sidered to measure both bound and free leptin, we cannot
make any inferences on the extent of plasma protein
binding. Nonetheless, these findings provide some of the
first information regarding the kinetics of exogenous
leptin in non human primates, and the results may be
applicable to humans.
Our failure to detect the log – linear elimination
phase within the 8 h sampling period following sub-
cutaneous administration suggests that the rate of
leptin absorption after subcutaneous administration
is quite slow, perhaps saturated. Zero order absorption
kinetics could potentially explain the near plateau
observed in Figure 1. This may have clinical signifi-
cance as route of administration and formulation are
considered for human administration.
As shown in previous studies, high fat fed mice
were found to have significantly increased baseline
circulating leptin levels.23 – 25 The mean baseline
plasma leptin concentration for high fat fed mice
was 43 24 ng=ml compared to 10 3 ng=ml in the
mice consuming the control diet. In contrast, there
was no statistical difference in any of the determined
pharmacokinetic parameters between the two groupsT
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of mice. Similarly, Klein et al found no differences in
leptin plasma clearance or half-life between normal
weight and obese human subjects.11 A study in obese
and lean Zucker rats also found no statistical differ-
ence in kinetics following intravenous administra-
tion.21 However, in that study, blood was only
collected during the first eight minutes after injection
and therefore little conclusions on the terminal
elimination phase could be drawn.
The steady-state level of endogenous leptin is equal
to the rate of whole body leptin production (LP)
divided by the clearance (CSS LP=Cl). Given that
clearance did not differ between the two groups of
mice, and assuming a similar fraction absorbed, the
four-fold higher base-line leptin levels in high-fat fed
mice must therefore be explained by an increase in
whole body leptin production of roughly the same
magnitude. A similar conclusion was made by Klein
et al based on their studies with obese humans.11 The
mean volumes of distribution observed in mice,
756 ml=kg in mice fed a normal diet and 702 ml=kg
in mice fed a high-fat diet indicate that leptin dis-
tributes into a much larger space than plasma volume.
Whether the large volume is attributable simply to
widespread distribution, or a significant contribution
is due to leptin binding to other proteins in the
extravascular space remains unknown. Compared to
monkeys, mice have a volume of distribution approxi-
mately three times larger and clear leptin six times
faster, although a caveat is that these values will be
affected by the fraction of leptin absorbed, as leptin
was administered by the intraperitoneal route in mice.
Nevertheless, even if absorption was incomplete, a
large difference in leptin kinetics would still exist in
mice compared with monkeys.
In conclusion, the results of these experiments
indicate that primates and rodents display similar
terminal elimination half-lives and mean residence
times for intravenously administered leptin. In con-
trast, clearance and the volume of distribution were
significantly different between the two species. It
should be emphasized that our conclusions are valid
for the pharmacokinetic characteristics of human
leptin in monkeys and mice. However, whether
these characteristics differ from species-specific
leptin remains to be established. Nonetheless,
marked differences in the pharmacokinetics of
human leptin between humans and rhesus monkeys
appear to be unlikely considering that the clearance of
human leptin in monkeys is similar to values pre-
viously observed in humans. Our results, together with
those from previously published studies,29 – 31 indicate
that the clearance of leptin does not appear to be a
saturated process at any point over the wide range of
doses employed in rats, primates and humans. In
addition, leptin administered extravascularly in
saline is absorbed slowly, with subcutaneous absorp-
tion appearing near zero-order. The present study also
found that there are no statistically significant differ-
ences in the pharmacokinetics of exogenous leptin
between normal weight chow-fed mice and mice
made obese by high-fat feeding, suggesting that
steady-state leptin levels in obesity do not result
from a decreased rate of elimination, but from an
increased rate of production and secretion.
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